Your browser doesn't support javascript.
loading
Depression-Anxiety Coupling Strength as a predictor of relapse in major depressive disorder: A CAN-BIND wellness monitoring study report.
Nunes, Abraham; Pavlova, Barbara; Cunningham, Jasmyn E A; Nuñez, John-Jose; Quilty, Lena C; Foster, Jane A; Harkness, Kate L; Ho, Keith; Lam, Raymond W; Li, Qingqin S; Milev, Roumen; Rotzinger, Susan; Soares, Claudio N; Taylor, Valerie H; Turecki, Gustavo; Kennedy, Sidney H; Frey, Benicio N; Rudzicz, Frank; Uher, Rudolf.
Afiliação
  • Nunes A; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Faculty of Computer Science, Dalhousie University, Halifax, Nova Scotia, Canada; Mood Disorders Program, Nova Scotia Health Authority, Halifax, NS, Canada. Electronic address: nunes@dal.ca.
  • Pavlova B; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Mood Disorders Program, Nova Scotia Health Authority, Halifax, NS, Canada.
  • Cunningham JEA; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Nuñez JJ; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Quilty LC; Campbell Family Mental Health Research Institute, CAMH, Toronto, ON, Canada.
  • Foster JA; Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; Mood Disorders Treatment and Research Centre, St. Joseph's Healthcare Hamilton, ON, Canada; Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA.
  • Harkness KL; Department of Psychology, Queen's University, Kingston, Ontario, Canada.
  • Ho K; Mood Disorders Treatment and Research Centre, St. Joseph's Healthcare Hamilton, ON, Canada.
  • Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Li QS; Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.
  • Milev R; Department of Psychiatry, Providence Care, Queen's University, Kingston, ON, Canada.
  • Rotzinger S; Mood Disorders Treatment and Research Centre, St. Joseph's Healthcare Hamilton, ON, Canada.
  • Soares CN; Department of Psychiatry, Providence Care, Queen's University, Kingston, ON, Canada.
  • Taylor VH; Cumming School of Medicine, Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
  • Turecki G; Douglas Institute, Department of Psychiatry, McGill University, Montreal, QC, Canada.
  • Kennedy SH; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Frey BN; Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; Mood Disorders Treatment and Research Centre, St. Joseph's Healthcare Hamilton, ON, Canada.
  • Rudzicz F; Faculty of Computer Science, Dalhousie University, Halifax, Nova Scotia, Canada; Vector Institute for Artificial Intelligence, Toronto, Ontario, Canada.
  • Uher R; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Mood Disorders Program, Nova Scotia Health Authority, Halifax, NS, Canada.
J Affect Disord ; 361: 189-197, 2024 Sep 15.
Article em En | MEDLINE | ID: mdl-38866253
ABSTRACT

BACKGROUND:

A critical challenge in the study and management of major depressive disorder (MDD) is predicting relapse. We examined the temporal correlation/coupling between depression and anxiety (called Depression-Anxiety Coupling Strength, DACS) as a predictor of relapse in patients with MDD.

METHODS:

We followed 97 patients with remitted MDD for an average of 394 days. Patients completed weekly self-ratings of depression and anxiety symptoms using the Quick Inventory of Depressive Symptoms (QIDS-SR) and the Generalized Anxiety Disorder 7-item scale (GAD-7). Using these longitudinal ratings we computed DACS as random slopes in a linear mixed effects model reflecting individual-specific degree of correlation between depression and anxiety across time points. We then tested DACS as an independent variable in a Cox proportional hazards model to predict relapse.

RESULTS:

A total of 28 patients (29 %) relapsed during the follow-up period. DACS significantly predicted confirmed relapse (hazard ratio [HR] 1.5, 95 % CI [1.01, 2.22], p = 0.043; Concordance 0.79 [SE 0.04]). This effect was independent of baseline depressive or anxiety symptoms or their average levels over the follow-up period, and was identifiable more than one month before relapse onset.

LIMITATIONS:

Small sample size, in a single study. Narrow phenotype and comorbidity profiles.

CONCLUSIONS:

DACS may offer opportunities for developing novel strategies for personalized monitoring, early detection, and intervention. Future studies should replicate our findings in larger, diverse patient populations, develop individual patient prediction models, and explore the underlying mechanisms that govern the relationship of DACS and relapse.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ansiedade / Recidiva / Transtorno Depressivo Maior Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Affect Disord Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ansiedade / Recidiva / Transtorno Depressivo Maior Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Affect Disord Ano de publicação: 2024 Tipo de documento: Article